15/03/2019 23:56:13

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corbus Pharmaceuticals Holdings, Inc. – CRBP

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corbus Pharmaceuticals Holdings, Inc. (“Corbus” or the “Company”) (NASDAQ: CRBP).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Corbus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On February 28, 2019, an article entitled “Corbus Has Ties to Suspect Investors And A History of Failed Clinical Trials for Lenabasum” was published on the website Seeking Alpha.  The article expressed the belief that lenabasum, Corbus’s lead product candidate, “has failed every trial,” “has a history of negative clinical data,” and “is likely to fail in the company’s pivotal trial in Scleroderma and Systemic Sclerosis (SSc) and Phase 2b trial in cystic fibrosis.”  The article further alleged “ties between Corbus . . . and a group of suspect investors that were involved during the company’s IPO.” 

Following the article’s publication, Corbus’s stock price fell $1.32 per share, or 15.98%, to close at $6.94 per share on February 28, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
I:SP500
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
71
23 Mar
 
Hej Kanonkugle   Der er endnu ikke inversrentekurve i USA, det måles som forskellen mellem den 2 og ..
15
25 Mar
BAVA
En ting er, at du sylter os ind i dit misforståede bavl om BAVA. Det er, hvad det er.    Noget andet..
14
19 Mar
VELO
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
14
23 Mar
CHEMM
Chemometec er ikke i nedtrend som helhed. Aktien har haft en foreløbig top. Har fundet en bund som e..
12
21 Mar
BAVA
Jeg synes bestemt også der skal være plads til kritikere af Bavarian. Der skal være plads til alle i..
12
21 Mar
PNDORA
Du rammer jo netop ned i strategien "NOW", hvor der kigges ind i hvilke butikker der er lønsomme. Sa..
12
20 Mar
ZEAL
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
12
21 Mar
I:SP500
Der er en alt afgørende ting som Rangvid ikke tager højde for, og som Lars Christensen glemmer at kr..
11
19 Mar
FING-B
Siden topformationen i 23 området har trenden krydset flere støttelinjer og er nu ved en mulig dobbe..
11

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UKTW I²P Celebrates First Successful Year of UK-TW Science Research Cooperation
2
ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia
3
Reminder - Product Tanker, Crude Oil Tanker, LNG, LPG and Chemical Tankers Sector Panel Discussions With Major Shipping Company Executives
4
Invitation by Aperam S.A. to holders of its outstanding U.S.$300,000,000 0.625 per cent. Net Share Settled Convertible and/or Exchangeable Bonds due 2021 (ISIN XS1084287322) (the “Bonds”) convertible into common shares of Aperam S.A. to off
5
Philips expands its radiology solutions offering with advanced teleradiology services

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 March 2019 03:03:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB7 - 2019-03-26 04:03:02 - 2019-03-26 03:03:02 - 1000 - Website: OKAY